Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.71129 ↗At a glance
Journal article in Diabetes, Obesity and Metabolism, 2026. Written by Eleanor McNally and 8 co-authors. Institution: School of Medicine and Population Health, University of Sheffield, Sheffield, UK. Major MEDLINE topics: Diabetes Mellitus, Type 1, Diabetic Retinopathy, Glycemic Control, Insulin Infusion Systems. Cited 1 times so far (Crossref); 38 references. The full text is freely available (open access, CC BY 4.0).
Topics: Diabetes mellitus
Abstract (original language)
Aims
To evaluate the real‐world effectiveness, safety, and tolerability of the Omnipod 5 hybrid closed‐loop system in adults with type 1 diabetes (T1D) with a novel focus on cardiometabolic markers alongside diabetic eye disease and renal function.
Methods
A single‐centre, retrospective analysis of adults with T1D using Omnipod 5 was conducted. Case notes were reviewed for routinely collected clinical data. Continuous glucose monitoring (CGM) metrics were obtained from cloud‐based platforms at 3, 6 and 12 months. Paired data were analysed with two‐tailed t ‐tests or Wilcoxon signed‐rank, with results presented as mean (SD) or median (IQR).
Results
One hundred individuals were included (63% female). At baseline, median age was 28 (23.0–37.8) years, BMI 27.0 (22.3–30.0) kg/m 2 , diabetes duration 16.0 (9.0–24.8) years and mean HbA1c 68 (±18.0) mmol/mol. Over half (52%) transitioned from multiple daily injections. Significant glycaemic improvements were observed by 3 months. Improvements were durable to 12 months, with mean HbA1c falling from 68.5 to 58.8 mmol/mol ( p < 0.001, n = 75) and time in range (TIR) increasing from 43.4% to 58.3% ( p < 0.001, n = 86). The greatest glycaemic improvements were observed in those with lower TIR at baseline. Retinopathy progression occurred in a minority of 10 individuals, all of whom had a baseline HbA1c > 53 mmol/mol.
Conclusions
Initiation of Omnipod 5 was associated with durable glycaemic improvements. Preliminary data generate the hypothesis that retinopathy progression may be concentrated among individuals with baseline HbA1c above target range. Prospective studies are required to evaluate long‐term retinal and cardiometabolic outcomes while controlling for concomitant weight and lipid‐lowering therapies.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Medicine and Population Health, University of Sheffield, Sheffield, UK.
- Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK.
ORCID profiles: Eleanor McNally, Simon Berry
Cite
APA
McNally, E., Goodman, I., Morris, R., Maliekkal, J., Saeed, D., Tan, H. W., Berry, S., Elliott, J., & Iqbal, A. (2026). Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.71129
Vancouver
McNally E, Goodman I, Morris R, Maliekkal J, Saeed D, Tan HW, et al. Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.71129
BibTeX
@article{McNally2026,
author = {McNally, Eleanor and Goodman, Iona and Morris, Rebecca and Maliekkal, John and Saeed, Dalha and Tan, Hao Wei and Berry, Simon and Elliott, Jackie and Iqbal, Ahmed},
title = {Looking Beyond Glycaemic Control: Real‐World 12‐Month Cardiometabolic and Retinopathy Outcomes Following Omnipod 5 Initiation in People With Type 1 Diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.71129}
}
EUVIMED